SCHEMBL2850490

SCHEMBL2850490

Nc1cccc(S(=O)(=O)NCCN2CCCC2)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.58
SIGMAR1 Q99720 7/20 0.58
PRMT1 Q99873 1/20 0.57
CYP19A1 P11511 1/20 0.54
PARP1 P09874 2/20 0.52
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TP53 P04637 1/20 0.51
MAPK1 P28482 1/20 0.51
SRC P12931 1/20 0.51
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
MBTD1 Q05BQ5 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2854997 0.99 SIGMAR1 (0.59) L3MBTL1SIGMAR1PRMT1CYP19A1PARP1
SCHEMBL17374111 0.89 PRMT1 (0.54) L3MBTL1SIGMAR1PRMT1CYP19A1MAPK1
SCHEMBL1361813 0.88 ALDH1A1 (0.64) PRMT1MAPK1
SCHEMBL2498510 0.83 L3MBTL1 (0.81) L3MBTL1SIGMAR1PARP1KDM4ELMNA
SCHEMBL5438202 0.82 SIGMAR1 (0.73) L3MBTL1SIGMAR1PRMT1KDM4ELMNA
SCHEMBL4617661 0.82 SFRP1 (0.61) L3MBTL1SIGMAR1PARP1KDM4ELMNA
Hydrochloric Acid SCHEMBL7966303 0.82 L3MBTL1 (0.79) L3MBTL1SIGMAR1PARP1KDM4ELMNA
SCHEMBL6568486 0.82 SIGMAR1 (0.72) L3MBTL1SIGMAR1PARP1KDM4ELMNA
SCHEMBL1565027 0.82 PRMT1 (0.73) PRMT1CYP19A1KDM4ELMNASMN1; SMN2
SCHEMBL31174173 0.82 PRMT1 (0.73) PRMT1CYP19A1KDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 L3MBTL1 4714/4885SIGMAR1 694/4885PRMT1 2611/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 L3MBTL1 4714/4885SIGMAR1 694/4885PRMT1 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.